Trial · NCT06333821

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

NCT06333821, Phase 3, Not yet recruiting, Biotech Pharmaceutical Co., Ltd.

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma. Trials, record NCT06333821. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06333821

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
NCT number: NCT06333821
Status: Not yet recruiting
Phases: Phase 3
Enrollment: 460 participants, estimated
Lead sponsor: Biotech Pharmaceutical Co., Ltd.
Conditions: Cervical Cancer
Interventions: Nimotuzumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy, placebo for Nimotuzumab
First posted: 2024-03-27
Last updated: 2024-03-27

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed Blinded Independent Central Review (BICR)	Up to approximately 5 years	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
Secondary	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by by the Investigator	Up to approximately 5 years	PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
Secondary	3-,5-Year Overall Survival (OS)	Up to approximately 3 and 5 years	OS is the time from randomization to death due to any cause.
Secondary	3-,5-Year Disease Free Survival(DFS)	Up to approximately 3 and 5 years	DFS is defined as the time from randomization to disease recurrence or death due to any cause.
Secondary	3-,5-Year Locoregional Recurrence-Free Survival(LRRFS)	Up to approximately 3 and 5 years	Locoregional recurrence-free survival (LRRFS) was defined as the absence of either consistent or relapsed disease at the primary tumor site or the regional lymph nodes
Secondary	3-,5-Year Distant Metastasis-free Survival (DMFS)	Up to approximately 3 and 5 years	Distant metastasis-free survival (DMFS) was calculated from the date of patient recruitment to the date of distant metastasis.
Secondary	Tumor Regression Rate(TRR)	From date of randomization until the date of brachytherapy,assessed up to 5 weeks	The maximum diameter represents the size of the tumor by MRI. Tumor size for each patient were obtained: pre-RT tumor size (V1), pre- brachytherapy tumor size (V2). TRR=(V1-V2)/V1 × 100%.
Secondary	Complete Response Rate	From date of randomization until the date of brachytherapy,assessed up to 5 weeks	The proportion of subjects with the best complete response in this group assessed by MRI.
Secondary	Complete Response Rate	3 months later after treatment	The proportion of subjects with the best complete response in this group assessed by MRI.
Secondary	Objective Response Rate	3 months later after treatment	The proportion of subjects with the best complete response or partial response in this group assessed by MRI.

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
41514314	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06333821

GET https://conductscience.org/api/trials/v1/NCT06333821/registered

API reference For AI assistants